SETD7 functions as a transcription repressor in prostate cancer via methylating FOXA1
Proceedings of the National Academy of Sciences · 2023
DOI: 10.1073/pnas.2220472120 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2023. Verfasst von Zifeng Wang und 16 weiteren Autor:innen. Beteiligte Einrichtung: Center for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, MA 02125. Hauptthemen laut MEDLINE: Histones, Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, HHS | NIH | National Cancer Institute, DOD | USA | MEDCOM | CDMRP | DOD Prostate Cancer Research Program.
Abstract (Originalsprache)
Dysregulation of histone lysine methyltransferases and demethylases is one of the major mechanisms driving the epigenetic reprogramming of transcriptional networks in castration-resistant prostate cancer (CRPC). In addition to their canonical histone targets, some of these factors can modify critical transcription factors, further impacting oncogenic transcription programs. Our recent report demonstrated that LSD1 can demethylate the lysine 270 of FOXA1 in prostate cancer (PCa) cells, leading to the stabilization of FOXA1 chromatin binding. This process enhances the activities of the androgen receptor and other transcription factors that rely on FOXA1 as a pioneer factor. However, the identity of the methyltransferase responsible for FOXA1 methylation and negative regulation of the FOXA1-LSD1 oncogenic axis remains unknown. SETD7 was initially identified as a transcriptional activator through its methylation of histone 3 lysine 4, but its function as a methyltransferase on nonhistone substrates remains poorly understood, particularly in the context of PCa progression. In this study, we reveal that SETD7 primarily acts as a transcriptional repressor in CRPC cells by functioning as the major methyltransferase targeting FOXA1-K270. This methylation disrupts FOXA1-mediated transcription. Consistent with its molecular function, we found that SETD7 confers tumor suppressor activity in PCa cells. Moreover, loss of SETD7 expression is significantly associated with PCa progression and tumor aggressiveness. Overall, our study provides mechanistic insights into the tumor-suppressive and transcriptional repression activities of SETD7 in mediating PCa progression and therapy resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, MA 02125.
- Department of Biology, University of Massachusetts Boston, Boston, MA 02125.
- Department of Medical Biophysics, University of Toronto, Toronto, ON M5G1L7, Canada.
- Princess Margaret Cancer Center, University Health Network, Toronto, ON M5G1L7, Canada.
- West China School of Public Health, West China Fourth Hospital and State Key Laboratory of Biotherapy, Sichuan University, Chengdu, Sichuan 610041, China.
- Department of Cell Biology and Anatomy, New York Medical College, Valhalla, NY 10595.
ORCID-Profile: Zifeng Wang, Muqing Li, Anna Besschetnova, Kellee R Siegfried, Jill A Macoska, Dong Han, Shuai Gao, Masoud Vedadi, Housheng Hansen He, Changmeng Cai
Förderung
- NCI NIH HHS
- HHS | NIH | National Cancer Institute
- DOD | USA | MEDCOM | CDMRP | DOD Prostate Cancer Research Program
- Canadian HIV Trials Network, Canadian Institutes of Health Research
- Terry Fox Research Institute
Zitieren
APA
Wang, Z., Petricca, J., Liu, M., Zhang, S., Chen, S., Li, M., Besschetnova, A., Patalano, S., Venkataramani, K., Siegfried, K. R., Macoska, J. A., Han, D., Gao, S., Vedadi, M., Arrowsmith, C. H., He, H. H., & Cai, C. (2023). SETD7 functions as a transcription repressor in prostate cancer via methylating FOXA1. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2220472120
Vancouver
Wang Z, Petricca J, Liu M, Zhang S, Chen S, Li M, et al. SETD7 functions as a transcription repressor in prostate cancer via methylating FOXA1. Proceedings of the National Academy of Sciences. 2023. doi:10.1073/pnas.2220472120
BibTeX
@article{Wang2023,
author = {Wang, Zifeng and Petricca, Jessica and Liu, Mingyu and Zhang, Songqi and Chen, Sujun and Li, Muqing and Besschetnova, Anna and Patalano, Susan and Venkataramani, Kavita and Siegfried, Kellee R and Macoska, Jill A and Han, Dong and Gao, Shuai and Vedadi, Masoud and Arrowsmith, Cheryl H and He, Housheng Hansen and Cai, Changmeng},
title = {SETD7 functions as a transcription repressor in prostate cancer via methylating FOXA1},
journal = {Proceedings of the National Academy of Sciences},
year = {2023},
doi = {10.1073/pnas.2220472120}
}
EUVIMED